In total, 100% (19 eyes) of the V4c group and 89.5% (17 eyes) of the V5 group showed UDVA [greater than or equal to] 20/20, respectively.
There were no significant differences in the 6-month postoperative CDVA between the V4c (20/12, -0.25[+ or -] 0.07 logMAR) and V5 groups (20/11, -0.26 [+ or -] 0.07 logMAR; p = 0.50).
A total of 94.7% (18 eyes) and 84.2% (16 eyes) were corrected to within [+ or -] 0.5 D of the target refraction in the V4c and V5 groups, respectively.
In the V4c group, 1, 14, and 4 eyes showed a low, moderate, or high vault, respectively, at 6 months after surgery.
Sixteen patients in the V4c group and 15 in the V5 group reported halos (Figure 1(b)).
The current study compared the efficacy, safety, and predictability of the V4c and the V5 ICL models.
ICL V4c implantation procedures were performed by an experienced surgeon (XZ).
The central anterior chamber depth (ACD), anterior chamber volume (ACV), anterior chamber angle width (ACAW), and the ICL V4c vault were measured using the Pentacam (Oculus, Germany) through a rotating Scheimpflug camera.
For the 31 eyes implanted with toric ICL V4c, a scatter plot with a best-fit line (y = 0.94x - 0.01, [R.sup.2] = 0.92) of the target versus the surgically induced astigmatism is shown in Figure 7.
The present study reported 2-year results after the ICL V4c implantation in a group of high-myopic patients.
Owing to the high percentage of super-high myopia (23% over -18.00 D) in the study group, the residual myopic diopters existed for they were beyond the ICL V4c correction range.
The combination of ICL V4c with corneal refractive surgery to treat super-high myopia could be further explored.